Jazz Pharmaceuticals plc

JAZZ · Nasdaq · ·

Comparar

240,40 US$-3,1 %cierre 12 nov

Cifras hasta el 30 de septiembre de 2026, del 10-Q presentado el 2 de noviembre de 2026

1W: +2,4 %
1M: +14,7 %

Acciones de Jazz Pharmaceuticals plc (JAZZ) — ¿es un buen negocio? — InspectStocks

Jazz Pharmaceuticals plc

JAZZ · Nasdaq · ·

Comparar

240,40 US$-3,1 %cierre 12 nov

Cifras hasta el 30 de septiembre de 2026, del 10-Q presentado el 2 de noviembre de 2026

1W: +2,4 %
1M: +14,7 %

Just reported

Q3 2026 results

From Jazz Pharmaceuticals's results release of 2 de noviembre de 2026; its quarterly report has since been filed.

Revenue
Actual
1,24B US$
+10 % y/y
+2,9 % q/q
Guided
—
No guide given
EPS, GAAP
Actual
-7,48 US$
Guided
—
No guide given
Operating income, GAAP
Actual
-413,4M US$
Guided
—
No guide given

Company outlook

Full year 2026

Revenue4,775B US$ – 4,85B US$+13 % y/y Raised +2,9 %

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Jazz Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Selección
Biotech
Por InspectStocks · 19 companies
Drug developers with approved medicines, built mainly on biologic and genetic science.
Precio, 1 año
+28,4 %
Ingresos, 1 año
+12,9 %
+13
A 8B 4C 5D 1F 1

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 355 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Cómo gana dinero

Xywav for narcolepsy and idiopathic hypersomnia41 %
Epidiolex for seizures associated with certain rare epilepsy conditions26 %
Rylaze for patients with leukemia or lymphoma who cannot take a common asparaginase medicine10 %
Zepzelca for small-cell lung cancer8 %
Xyrem for narcolepsy4 %

Los porcentajes de ingresos son estimaciones para 2025, no cifras de un informe oficial.

Compite con

Qué vende6

Xywav
A low-sodium liquid medicine for cataplexy and excessive daytime sleepiness in people with narcolepsy, and for idiopathic hypersomnia in adults.
Epidiolex
A purified cannabidiol liquid medicine used to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.
Ziihera
An antibody medicine for certain cancers with high levels of human epidermal growth factor receptor 2 (HER2), including bile duct cancer and, in the United States, stomach and related cancers.

Mostrar 3 más

Modeyso
A medicine for diffuse midline glioma with an H3 K27M mutation that has progressed after earlier treatment; it is also approved for this condition in Japan.
Zepzelca
A cancer medicine used with atezolizumab as maintenance treatment for some adults with extensive-stage small-cell lung cancer.
Rylaze
An injectable medicine used as part of chemotherapy for acute lymphoblastic leukemia or lymphoblastic lymphoma when a patient is hypersensitive to an E. coli-derived medicine.

Quién se lo compra5

Patients use Jazz's medicines under prescriptions from healthcare professionals.
ESSDS is the certified specialty pharmacy that receives U.S. Xywav and Xyrem and ships them directly to patients.
Onco360 is the certified specialty pharmacy that ships Modeyso directly to patients in the United States.

Mostrar 2 más

Specialty pharmacies and distributors supply Epidiolex to patients and healthcare providers.
McKesson, Cencora and Cardinal distribute Zepzelca, Rylaze, Ziihera and other medicines to hospitals and healthcare customers.

En qué se apoya y qué podría romperlo

De qué depende el negocio

1The business continues to depend substantially on Xywav sales and on maintaining physician and patient use and insurance coverage for it.
2Xywav and Xyrem require a restricted distribution system: prescriptions must go through a certified pharmacy under a Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy.
3Jazz relies on outside manufacturers and suppliers for many medicines. Patheon supplies several products, and the company identifies sole-source suppliers for products including Modeyso and Vyxeos.
4Sales depend on regulatory approvals, continued access to reimbursement from insurers and pharmacy benefit managers, and the results of required follow-up trials for some accelerated approvals.

Qué podría salir mal

1Generic high-sodium oxybate medicines, branded alternatives and new sleep-disorder treatments may reduce demand for Xywav and Xyrem or lead insurers to offer less favorable coverage.
2Epidiolex sales depend on continued prescribing and insurance reimbursement; the medicine also faces competition from other seizure treatments and could face generic competition under patent-settlement terms or earlier in certain circumstances.
3Some cancer medicines have accelerated or conditional approvals that depend on follow-up trials; unsuccessful trials or regulatory action could restrict or remove an approval, as happened when the second-line small-cell lung cancer indication for Zepzelca was removed in September 2026.

Estados financieros completos →

Sobre Jazz Pharmaceuticals plc

Jazz develops and sells prescription medicines, focusing on rare sleep disorders, epilepsy and cancers. Its largest products include Xywav for narcolepsy and idiopathic hypersomnia and Epidiolex for seizures linked to certain rare conditions. It also sells cancer medicines and runs clinical trials to test new medicines and uses for existing ones. At September 30, 2026, about 17,550 patients were taking Xywav (high confidence).

Sede: Dublin, Ireland
Fundada en: 2003
Empleados: 2,890 (December 31, 2025, high)
Cotiza en: Nasdaq
Cierre del ejercicio: December 31

Construido a partir de los propios informes de Jazz Pharmaceuticals plc ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.

Just reported